Project Grant R00HL161491
Award Date
7/15/24
Completion Date
6/30/27
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a $433,824 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research aimed at understanding the metabolic mechanisms underlying diabetic cardiomyopathy. The project will leverage induced pluripotent stem cell (iPSC) technology to generate cardiovascular cell models of type 2 diabetes and assess the impact of SGLT2 inhibition on cellular and metabolic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) totals $691,614.00 and will be executed from December 15, 2024 to November 30, 2028. The award supports research at Rhode Island Hospital, a division of Lifespan Corporation, to investigate how post-translational modifications of the enzyme CaMKII during chronic diabetes dysregulate endothelial small-conductance calcium-activated potassium (SK)...
This $323,277 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to identify mechanisms of right ventricular (RV) dysfunction in type 2 diabetes. The key goals are to 1) determine how fatty acid uptake contributes to RV lipotoxicity and dysfunction, and 2) identify causes of impaired reactive oxygen species signaling in the diabetic RV. This novel research aims to advance...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $543,268 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Beckman Research Institute of the City of Hope. This grant aims to elucidate the RNA-mediated epigenetic and epitranscriptional mechanisms underlying diabetes-associated endotheliopathy, in order to develop novel therapeutics to ameliorate diabetic vasculopathy.
The research will be conducted across three interconnected projects: 1)...
This $126,442 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of Minnesota to determine the effects of hyperglycemia and glycemic recovery on aortic biomechanics and mechanobiology. The central hypothesis is that chronic hyperglycemia leads to cellular and matrix changes in the aorta, and that while glycemic recovery can reverse the cellular changes, the matrix...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the relationship between cellular metabolism, inflammatory signaling, and epigenetic regulation in the context of vascular regeneration and cell transdifferentiation. The $1,245,515.38 award to The Methodist Hospital Research Institute Division aims to determine the molecular metabolic pathways that facilitate the...
This Project Grant award of $154,568 from the National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) supports research to characterize the underlying causes of cardiometabolic distress resulting from lipoic acid deficiency. The award recipient, The University of Texas Southwestern Medical Center, will use novel mouse models to study how defects in the LIPT1 gene, which is critical for lipoic acid synthesis, can disrupt cardiac metabolism and...
This federal Project Grant award of $249,000 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support the development of microphysiological systems to study hypoxic cardiac injury. The project aims to engineer microfluidic devices that can precisely control oxygen levels to investigate the molecular pathways and functional effects on cardiomyocytes under oxygen gradients, as observed during myocardial infarction...
This Project Grant award, valued at $167,400.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), to Brigham & Women's Hospital Inc. to conduct research on the role of the immune mediator CD70 in regulating endothelial function and vascular dysfunction.
The key objectives of this research are to:
Elucidate how CD70 regulates endothelial nitric oxide synthase (eNOS) and bioactive nitric oxide...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $375,988 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The award, effective May 20, 2024 through December 1, 2026, will support research to examine the interactions between mutant endothelial cells and mural cells/macrophages in capillary malformations, a common vascular disorder. The project aims to provide new...